Harrow Health Inc (HROW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harrow Health Inc (HROW) has a cash flow conversion efficiency ratio of 0.356x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($16.59 Million) by net assets ($46.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Harrow Health Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Harrow Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Harrow Health Inc for a breakdown of total debt and financial obligations.
Harrow Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harrow Health Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mader Group Ltd
AU:MAD
|
0.132x |
|
Astec Industries Inc
NASDAQ:ASTE
|
0.052x |
|
Meren Energy Inc.
NASDAQ:MRNFF
|
0.097x |
|
Bega Cheese Ltd
AU:BGA
|
-0.040x |
|
Arbor Realty Trust
NYSE:ABR
|
0.057x |
|
China Railway Tielong Container Logistics Co Ltd
SHG:600125
|
0.023x |
|
Astra Microwave Products Limited
NSE:ASTRAMICRO
|
-0.078x |
|
Stepan Company
NYSE:SCL
|
0.056x |
Annual Cash Flow Conversion Efficiency for Harrow Health Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Harrow Health Inc from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Harrow Health Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $69.30 Million | $-22.20 Million | -0.320x | -684.06% |
| 2023-12-31 | $70.00 Million | $3.84 Million | 0.055x | -13.50% |
| 2022-12-31 | $26.89 Million | $1.71 Million | 0.063x | -86.36% |
| 2021-12-31 | $10.93 Million | $5.08 Million | 0.465x | +1233.89% |
| 2020-12-31 | $26.83 Million | $-1.10 Million | -0.041x | -218.34% |
| 2019-12-31 | $27.42 Million | $950.00K | 0.035x | +24.83% |
| 2018-12-31 | $24.75 Million | $687.00K | 0.028x | +100.82% |
| 2017-12-31 | $2.62 Million | $-8.80 Million | -3.366x | -93.07% |
| 2016-12-31 | $6.43 Million | $-11.21 Million | -1.744x | -121.67% |
| 2015-12-31 | $-1.39 Million | $-11.14 Million | 8.045x | +1029.39% |
| 2014-12-31 | $8.15 Million | $-7.06 Million | -0.866x | -194.69% |
| 2013-12-31 | $15.11 Million | $-4.44 Million | -0.294x | -54.49% |
| 2012-12-31 | $10.00 Million | $-1.90 Million | -0.190x | -211.02% |
| 2011-12-31 | $-1.70 Million | $-291.16K | 0.171x | -92.26% |
| 2010-12-31 | $-1.04 Million | $-2.30 Million | 2.214x | +135.78% |
| 2009-12-31 | $577.21K | $-3.57 Million | -6.186x | -1016.35% |
| 2008-12-31 | $4.57 Million | $-2.53 Million | -0.554x | -9.67% |
| 2007-12-31 | $3.49 Million | $-1.76 Million | -0.505x | +82.02% |
| 2006-12-31 | $21.35K | $-60.00K | -2.810x | -145.49% |
| 2005-12-31 | $34.99K | $-40.06K | -1.145x | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, … Read more